Science

A differentiated PLK1 inhibitor.

plogosertib (THT-140) is being developed as an oral PLK1 inhibitor for cancer indications. PLK1 is a well-characterized oncology target with a strong scientific rationale across multiple tumor types.

View pipeline

Differentiation

Why plogosertib (THT-140)

Unique PLK1-targeted drug

A differentiated PLK1 chemistry developed for treating cancer.

Oral, short half-life

Oral small-molecule with a relatively short half-life — supporting flexible dosing.

Supplementary BRD4 activity

Secondary BRD4 inhibitory activity alongside PLK1 inhibition.

New PLK1 pathways

Identified new pathways for PLK1 inhibitory activity beyond classical mitotic arrest.

Biomarker-defined

Development guided by biomarker-defined patient selection across indications.

Data & disclosures

Detailed mechanism, preclinical, and clinical data will be disclosed through peer-reviewed publications, conference presentations, and regulatory filings as the program progresses. Active and planned trials will be listed on this site as ClinicalTrials.gov records become available.

Selected references

  1. Medema RH et al. Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy. Clin Cancer Res 2011;17(20):6459–66.

Tethra-authored publications and conference presentations will be added to Publications & resources.